HIMS & HERS HEALTH, INC. for HIMS & HERS HEALTH, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 20, 2025 | $310,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Oct 20, 2025 | $320,000 | Replaced |
| 3rd Quarter - Amendment | Jan 23, 2026 | $330,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SONYA ELLING | — |
| WHITNEY JONES New | Health Policy Analyst, Sen. Rep. Pol. Comm. (2018-2022) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.